MedPharm Expands Relationship With Novan
MedPharm Expands Relationship With Novan On Formulation Science. MedPharm Ltd, a leader in topical and transdermal drug delivery, has expanded its relationship with the NASDAQ listed biopharmaceutical company Novan Inc.
MedPharm has previously supported Novan by testing the company’s unique formulations using its proprietary in vitro models to optimise Novan’s formulations and de-risk product development.
The newly expanded agreement between the companies will broaden the relationship to include development of formulations and selection of product candidates, cost-effective product target screening and the development of in vitro models focused on Novan’s nitric oxide product technology.
“MedPharm is delighted to be able to support Novan in advancing and broadening its product pipeline,” commented Eugene Ciolfi, MedPharm’s President & CEO. “Our new agreement allows us to react quickly to changes in requirements and makes full use of MedPharm’s comprehensive services for de-risking Novan’s product development”.
“Novan recognises MedPharm has in-depth experience in developing new topical products fit for commercialisation”, added Paula Brown Stafford, Novan’s President and Chief Operating Officer. “The team’s responsiveness, rigorous scientific approach and specialised knowledge makes MedPharm an ideal partner to help Novan achieve its objectives.”
Notes to editors
MedPharm is the world’s leading contract provider of topical and transdermal product design and formulation development services. MedPharm are experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through their unique, cost-effective and industry-leading performance testing models. Well established as the global leaders in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm can also offer innovative solutions for ophthalmic and airway preparations recognised for their scientific rigour by regulators and investors. MedPharm has fully established R&D centres in the USA and UK and has its global HQ in Guildford, UK.
Novan, Inc. is a clinical development-stage biotechnology company focused on leveraging nitric oxide’s naturally occurring anti-microbial and immunomodulatory mechanisms of action to treat a range of diseases with significant unmet needs. We believe that our ability to deploy nitric oxide in a solid form, on demand and in localized formulations allows us the potential to improve patient outcomes in a variety of dermatological, women’s health and gastrointestinal diseases.